Synaxys
- Company typePrivate
- Founded2018
- HeadquartersToulouse, France
- Headcount1–10
- GTM typeB2B
- OfferingServices
Synaxys firmographics
Firmographics- Name
- Synaxys
- Legal name
- SYNAXYS SAS
- Website
- https://synaxys.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
Synaxys industry classification
Industry- Product category
- Preclinical Contract Research Services
- NAICS
- Research and Development in the Physical, Engineering, and Life Sciences (54171), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Nonclinical Study Management & Regulatory Writing (IND-enabling) (HLAGAFAN)
Keywords
Where Synaxys is headquartered
LocationHeadquarters
- HQ city
- Toulouse
- HQ country
- France
- HQ region
- Europe
Offices1 record
Markets served
Synaxys business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- Contract Research Services: Synaxys operates as a Contract Research Organization (CRO) providing custom-designed preclinical assays and R&D projects. They offer pilot tests, neuro-pharmacology studies, and full R&D projects with comprehensive confidential reports directly usable for decision-making. Revenue is generated through service fees for customized research studies.
- R&D Partnerships: Collaborative R&D projects with public or private institutions. Synaxys participates as partner to answer research calls or as coordinator to design and manage R&D projects. Revenue may come from government grants (e.g., ANR-PRCE) and collaborative research agreements.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
Synaxys product offering
Product offeringCore offering
Synaxys is a Contract Research Organization providing custom-designed preclinical research services built on its proprietary 5D-brain technology, a human in vitro 3D neuronal network model. The company delivers pilot tests, neuro-pharmacology studies, and full R&D projects to pharmaceutical and biotech clients to predict human nervous system responses and evaluate neurological disease therapeutics before clinical trials.
Product overview
Synaxys offers a unified platform centered on its 5D-brain product, a proprietary 3D human in vitro neuronal network model for preclinical research. The portfolio includes complementary service tiers: Pilot Tests for dose-response characterization, Neuro-pharmacology Studies for target identification, and Full R&D Projects leveraging disease-specific models (healthy reference and epileptic). The 5D-brain serves as the core enabling technology across all services, delivering functional electrophysiological data, microscopy, genomic and proteomic analysis to predict human nervous system responses before clinical trials.
Differentiator
Problem solved
Functional benefit
Brands
- 5D-brain: The first reliable human in vitro model of the nervous system for functional preclinical studies, offering 5 dimensions (X, Y, Z, time, activity) to replace animal experimentation
- 5D-BRAIN
Products and services
- 5D-brain The first reliable human in vitro model of the nervous system for functional preclinical studies, providing five accessible dimensions (X, Y, Z, time, activity) to replace animal experimentation and enhance preclinical R&D results. It is sold as the foundational technology platform underlying Synaxys' CRO service offerings.
- Pilot Tests Custom-designed CRO service for characterization of dose response for client compounds compared to reference chemicals on a healthy mature 3D human neuronal network. Targeted at pharmaceutical and biotech R&D teams needing initial preclinical characterization.
- Neuro-pharmacology Studies Custom CRO service covering identification of biological targets of client compounds and determination of specific characteristics compared to known drugs with similar targets. Targeted at drug discovery teams in pharma and biotech.
- Full R&D Projects End-to-end custom CRO project evaluating the therapeutic potential of compounds using 5D-brain disease models, with two models currently available: healthy reference and epileptic model. Delivered as a thorough confidential report directly usable for decision-making. Targeted at pharmaceutical and biotech R&D teams.
Quantifiable outcome
- Delivers reliable preclinical data in less than 3 weeks
- +2 more outcomes
Companies that use Synaxys
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles3 records
Synaxys technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Synaxys partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core and minor.
- EurobiomedcoreSynaxys joined Eurobiomed in September 2019, a competitiveness cluster supporting healthcare innovation in the South of France, providing industry networking and partnership opportunities.
- CNRS (Centre National de la Recherche Scientifique)coreLicense agreement signed in December 2018 granting Synaxys rights to technologies developed at CNRS. CNRS also provided housing at ITAV research institute starting November 2017, enabling Synaxys to launch operations.
- SATT-TTT (Société d'Accélération de Transfert de Technologies Toulouse Tech)coreLicense agreement signed in December 2018 alongside CNRS for technology transfer of proprietary neuro-engineering processes.
- LAAS-CNRS (Laboratoire d'Analyse et d'Architecture des Systèmes)minorResearch partner providing scientific expertise and laboratory resources for Synaxys' neuro-engineering research activities.
- IRIT (Institut de Recherche en Informatique de Toulouse)minorResearch partner contributing expertise in data analysis and computational methods for Synaxys' big data analysis capabilities.
- UT3PS (Université Toulouse III Paul Sabatier)minorAcademic research partner providing scientific collaboration and research expertise in neuroscience and related fields.
- NUBBOminorListed as a research partner in Synaxys' ecosystem, nature of collaboration not detailed.
Scale indicators4 records
Recent moves6 records
Expansion highlights5 records
Synaxys competitors and assessment
Company assessmentBroad incumbents
- Eurofins Discovery: Eurofins Discovery offers large-scale preclinical and discovery services including CNS/neuroscience assays, positioning it as a broad incumbent that competes with Synaxys for outsourced preclinical research contracts.
- Charles River Laboratories: Charles River is a global CRO offering preclinical neuroscience safety and efficacy assessment services, representing a broad incumbent competitor that pharma clients may choose instead of specialized platforms like Synaxys.
- Fujifilm Cellular Dynamics: Fujifilm CDI is a major supplier of iPSC-derived cells including iCell neurons, providing off-the-shelf human neuronal cells that partially substitute for Synaxys' custom 5D-brain models in pharma screening workflows.
Direct peers
- Neuroservice: Neuroservice is a CRO specializing in electrophysiology and CNS preclinical services, making it a direct functional competitor to Synaxys for pharma outsourced neuroscience assay work.
- Axol Bioscience: Axol Bioscience supplies iPSC-derived neural cell types and custom neuroscience services for drug discovery, overlapping with Synaxys on human neuronal models and preclinical assay offerings.
- BrainXell: BrainXell specializes in iPSC-derived neuron production and neural differentiation services for neuroscience drug discovery, overlapping with Synaxys on human neuronal models and preclinical assay offerings.
- Ncardia: Ncardia provides iPSC-derived cardiac and neural cells and assay services for drug discovery, directly competing with Synaxys in human iPSC-based neuronal models for preclinical neuroscience applications.
- StemoniX (part of Cancer Genetics Inc./Vyant Bio): StemoniX develops microBrain 3D human neural platforms and screening services for CNS drug discovery, making it a direct competitor to Synaxys' 5D-brain in functional neuronal assay services.
Emerging players
- bit.bio: bit.bio programs iPSCs into mature human cell types at scale using its opti-ox technology, supplying defined neuronal populations that compete with parts of Synaxys' human neuron differentiation pipeline.
- Mimetas: Mimetas develops organ-on-chip and 3D tissue models for drug discovery including neurological applications, intersecting with Synaxys' 3D human in vitro preclinical approach.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
Synaxys social profiles
Digital presenceSynaxys compliance and trust
Trust signalCompliance2 records
Synaxys financial estimates
Financial estimateRevenue estimate
Valuation estimate
Synaxys leadership team
Management profileNumber of profiles
Profiles2 records
Synaxys funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Synaxys M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Synaxys
What does Synaxys do?
Synaxys is a Contract Research Organization providing custom-designed preclinical research services built on its proprietary 5D-brain technology, a human in vitro 3D neuronal network model. The company delivers pilot tests, neuro-pharmacology studies, and full R&D projects to pharmaceutical and biotech clients to predict human nervous system responses and evaluate neurological disease therapeutics before clinical trials.
Is Synaxys a public or private company?
Synaxys is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Synaxys founded?
Synaxys was founded in 2018. It employs 1 to 10 people.
Where is Synaxys based?
Synaxys is headquartered in Toulouse, France, in the Europe region.
How does Synaxys make money?
Two revenue lines are on record. Contract Research Services are the primary driver. The others are R&D Partnerships.
Who are Synaxys's main competitors?
Broad incumbents on record are Eurofins Discovery, Charles River Laboratories and Fujifilm Cellular Dynamics. Direct peers are Neuroservice, Axol Bioscience, BrainXell, Ncardia and StemoniX (part of Cancer Genetics Inc./Vyant Bio). Emerging players are bit.bio and Mimetas.
Does Synaxys have an API?
No public API is recorded for Synaxys.
What industry is Synaxys in?
Synaxys's product category is Preclinical Contract Research Services. Its primary akta.pro industry code is HLAGAFAN, Nonclinical Study Management & Regulatory Writing (IND-enabling). Its NAICS code is 54171 and its SIC code is 8731.